The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells

Molecular and Cellular Biology

Volumn 35, Issue 8, 2015, Pages 1350-1362

  Zhang, Lin ^a,b   Yang, Shuping ^a,b,d   Chen, Xingcheng ^a,b   Stauffer, Seth ^a,b   Yu, Fang ^a   Lele, Subodh M ^b   Fu, Kai ^b   Datta, Kaustubh ^b   Palermo, Nicholas ^c   Chen, Yuanhong ^a   Dong, Jixin ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN; S6 KINASE; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; HIPPO PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVATION; CELL DIVISION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HEK293 CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CASTRATION; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SCID MOUSE; TUMOR INVASION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANDROGENS; ANIMALS; CASTRATION; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE, SCID; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84925381625     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00102-15     Document Type: Article

References (82)

1. Amaral TM, Macedo D, Fernandes I, Costa L. 2012. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer 2012:327253. http://dx.doi.org/10.1155/2012/327253.
2. Chen Y, Sawyers CL, Scher HI. 2008. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8:440-448. http://dx.doi.org/10.1016/j.coph.2008.07.005.
3. Zhao B, Li L, Lei Q, Guan KL. 2010. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 24:862-874. http://dx.doi.org/10.1101/gad.1909210.
4. Pan D. 2010. The Hippo signaling pathway in development and cancer. Dev Cell 19:491-505. http://dx.doi.org/10.1016/j.devcel.2010.09.011.
5. Harvey KF, Zhang X, Thomas DM. 2013. The Hippo pathway and human cancer. Nat Rev Cancer 13:246-257. http://dx.doi.org/10.1038/nrc3458.
6. Park HW, Guan KL. 2013. Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci 34:581-589. http://dx.doi.org/10.1016/j.tips.2013.08.006.
7. Johnson R, Halder G. 2014. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 13:63-79. http://dx.doi.org/10.1038/nrd4161.
8. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM, Lim DS. 2010. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A 107:8248-8253. http://dx.doi.org/10.1073/pnas.0912203107.
9. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, Johnson RL. 2010. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A 107:1437-1442. http://dx.doi.org/10.1073/pnas.0911427107.
10. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM, Wang CY, Gao B, Jiang J, Yang Y. 2010. Mammalian MstI and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A 107:1431-1436. http://dx.doi.org/10.1073/pnas.0911409107.
11. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, Bardeesy N. 2009. MstI and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16:425-438. http://dx.doi.org/10.1016/j.ccr.2009.09.026.
12. Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G, Lu D. 2006. Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 56:450-458. http://dx.doi.org/10.1016/j.neures.2006.09.006.
13. Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, Ranganathan S, Apte U. 2012. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int 32:38-47. http://dx.doi.org/10.1111/j.1478-3231.2011.02646.x.
14. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S, Taubert H, Dammann R. 2007. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 46:865-871. http://dx.doi.org/10.1002/mc.20317.
15. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S. 2005. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 11:1380-1385. http://dx.doi.org/10.1158/1078-0432.CCR-04-1773.
16. Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, Toyokuni S, Osada H, Sekido Y. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71:873-883. http://dx.doi.org/10.1158/0008-5472.CAN-10-2164.
17. Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J, Brummelkamp TR, Camargo FD. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 144:782-795. http://dx.doi.org/10.1016/j.cell.2011.02.031.
18. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D. 2007. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130:1120-1133. http://dx.doi.org/10.1016/j.cell.2007.07.019.
19. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR. 2007. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17:2054-2060. http://dx.doi.org/10.1016/j.cub.2007.10.039.
20. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. 2006. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 103:12405-12410. http://dx.doi.org/10.1073/pnas.0605579103.
21. Tremblay AM, Missiaglia E, Galli GG, Hettmer S, Urcia R, Carrara M, Judson RN, Thway K, Nadal G, Selfe JL, Murray G, Calogero RA, De Bari C, Zammit PS, Delorenzi M, Wagers AJ, Shipley J, Wackerhage H, Camargo FD. 2014. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell 26:273-287. http://dx.doi.org/10.1016/j.ccr.2014.05.029.
22. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW. 2006. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125:1253-1267. http://dx.doi.org/10.1016/j.cell.2006.05.030.
23. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. 2008. Expression of Yes-associated protein in common solid tumors. Hum Pathol 39:1582-1589. http://dx.doi.org/10.1016/j.humpath.2008.04.012.
24. Fernandez-L A, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, Taylor MD, Kenney AM. 2009. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehogdriven neural precursor proliferation. Genes Dev 23:2729-2741. http://dx.doi.org/10.1101/gad.1824509.
25. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM. 2009. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115:4576-4585. http://dx.doi.org/10.1002/cncr.24495.
26. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL. 2007. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747-2761. http://dx.doi.org/10.1101/gad.1602907.
27. Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, AOCS Study Group, Bowtell DD, Harvey KF. 2011. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 30:2810-2822. http://dx.doi.org/10.1038/onc.2011.8.
28. Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, Wellstein A, Yi C. 2014. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal 7:ra42. http://dx.doi.org/10.1126/scisignal.2005049.
29. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. 2012. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA 109:E2441-E2450. http://dx.doi.org/10.1073/pnas.1212021109.
30. Yu FX, Guan KL. 2013. The Hippo pathway: regulators and regulations. Genes Dev 27:355-371. http://dx.doi.org/10.1101/gad.210773.112.
31. Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, Shao DD, Schumacher SE, Weir BA, Vazquez F, Cowley GS, Root DE, Mesirov JP, Beroukhim R, Kuo CJ, Goessling W, Hahn WC. 2012. Beta-catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151:1457-1473. http://dx.doi.org/10.1016/j.cell.2012.11.026.
32. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, Wrana JL, Attisano L. 2010. The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell 18:579-591. http://dx.doi.org/10.1016/j.devcel.2010.03.007.
33. Imajo M, Miyatake K, Iimura A, Miyamoto A, Nishida E. 2012. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling. EMBO J 31:1109-1122. http://dx.doi.org/10.1038/emboj.2011.487.
34. Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, Martin JF. 2011. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332:458-461. http://dx.doi.org/10.1126/science.1199010.
35. Konsavage WM, Jr, Kyler SL, Rennoll SA, Jin G, Yochum GS. 2012. Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem 287:11730-11739. http://dx.doi.org/10.1074/jbc.M111.327767.
36. Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M, Piccolo S. 2012. Role of TAZ as mediator of Wnt signaling. Cell 151:1443-1456. http://dx.doi.org/10.1016/j.cell.2012.11.027.
37. Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, Fassina A, Cordenonsi M, Piccolo S. 2014. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 158:157-170. http://dx.doi.org/10.1016/j.cell.2014.06.013.
38. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ, Sapkota G, Pan D, Massague J. 2009. Nuclear CDKs drive Smad transcriptional activation and turnover inBMPand TGF-beta pathways. Cell 139:757-769. http://dx.doi.org/10.1016/j.cell.2009.09.035.
39. Ferrigno O, Lallemand F, Verrecchia F, L'Hoste S, Camonis J, Atfi A, Mauviel A. 2002. Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling. Oncogene 21:4879-4884. http://dx.doi.org/10.1038/sj.onc.1205623.
40. Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW, Wrana JL. 2008. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stemcell self-renewal. Nat Cell Biol 10:837-848. http://dx.doi.org/10.1038/ncb1748.
41. Xin M, Kim Y, Sutherland LB, Qi X, McAnally J, Schwartz RJ, Richardson JA, Bassel-Duby R, Olson EN. 2011. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci Signal 4:ra70. http://dx.doi.org/10.1126/scisignal.2002278.
42. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, Zender L, Lowe SW, Hong W, Luk JM. 2011. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 30:1229-1240. http://dx.doi.org/10.1038/onc.2010.504.
43. Yang S, Zhang L, Liu M, Chong R, Ding SJ, Chen Y, Dong J. 2013. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res 73:6722-6733. http://dx.doi.org/10.1158/0008-5472.CAN-13-2049.
44. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. 1994. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577-2581. http://dx.doi.org/10.1126/scisignal.2002278.
45. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF. 1998. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 273:5939-5947. http://dx.doi.org/10.1074/jbc.273.10.5939.
46. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. 2002. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50:222-235. http://dx.doi.org/10.1002/pros.10054.
47. Xiao L, Chen Y, Ji M, Dong J. 2011. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases. J Biol Chem 286:7788-7796. http://dx.doi.org/10.1074/jbc.M110.173468.
48. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL. 2008. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22:1962-1971. http://dx.doi.org/10.1101/gad.1664408.
49. Johnson KR, Lewis JE, Li D, Wahl J, Soler AP, Knudsen KA, Wheelock MJ. 1993. P- and E-cadherin are in separate complexes in cells expressing both cadherins. Exp Cell Res 207:252-260. http://dx.doi.org/10.1006/excr.1993.1191.
50. Xiao L, Chen Y, Ji M, Volle DJ, Lewis RE, Tsai MY, Dong J. 2011. KIBRA protein phosphorylation is regulated by mitotic kinase aurora and protein phosphatase 1. J Biol Chem 286:36304-36315. http://dx.doi.org/10.1074/jbc.M111.246850.
51. Yang S, Ji M, Zhang L, Chen Y, Wennmann DO, Kremerskothen J, Dong J. 2014. Phosphorylation of KIBRA by the extracellular signal-regulated kinase (ERK)-ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration. Cell Signal 26:343-351. http://dx.doi.org/10.1016/j.cellsig.2013.11.012.
52. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, Lee JH, Wadhwa R, Sudo K, Stroehlein JR, Martin JF, Hung MC, Johnson RL. 2014. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stemlike properties. Cancer Res 74:4170-4182. http://dx.doi.org/10.1158/0008-5472.CAN-13-3569.
53. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674. http://dx.doi.org/10.1016/j.cell.2011.02.013.
54. Chambers AF, Groom AC, MacDonald IC. 2002. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563-572. http://dx.doi.org/10.1038/nrc865.
55. Chaffer CL, Weinberg RA. 2011. A perspective on cancer cell metastasis. Science 331:1559-1564. http://dx.doi.org/10.1126/science.1203543.
56. Nguyen DX, Bos PD, Massague J. 2009. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274-284. http://dx.doi.org/10.1038/nrc2622.
57. Hong SK, Jeong JH, Chan AM, Park JI. 2013. AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. Exp Cell Res 319:1732-1743. http://dx.doi.org/10.1016/j.yexcr.2013.05.008.
58. Karan D, Schmied BM, Dave BJ, Wittel UA, Lin MF, Batra SK. 2001. Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations. Clin Cancer Res 7:3472-3480.
59. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK. 2002. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23:967-975. http://dx.doi.org/10.1093/carcin/23.6.967.
60. Qin J, Xie Y, Wang B, Hoshino M, Wolff DW, Zhao J, Scofield MA, Dowd FJ, Lin MF, Tu Y. 2009. Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis. Oncogene 28:1853-1863. http://dx.doi.org/10.1038/onc.2009.30.
61. Mulholland DJ, Dedhar S, Wu H, Nelson CC. 2006. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 25:329-337. http://dx.doi.org/10.1038/sj.onc.1209020.
62. Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M. 2012. MAP kinases and prostate cancer. J Signal Transduct 2012:169170. http://dx.doi.org/10.1155/2012/169170.
63. Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo FD, Guan KL. 2012. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 14:1322-1329. http://dx.doi.org/10.1038/ncb2615.
64. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. 2010. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 16:1414-1420. http://dx.doi.org/10.1038/nm.2236.
65. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39. http://dx.doi.org/10.1038/nm972.
66. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. 2009. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76-85. http://dx.doi.org/10.1038/ncpuro1296.
67. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Janne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M. 2009. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245-256. http://dx.doi.org/10.1016/j.cell.2009.04.056.
68. Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, Mirzaei H, Auchus RJ, Sharifi N. 2013. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154:1074-1084. http://dx.doi.org/10.1016/j.cell.2013.07.029.
69. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. 2013. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A 110:E4762-E4769. http://dx.doi.org/10.1073/pnas.1319948110.
70. Gleave M, Miyake H, Chi K. 2005. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol 56(Suppl 1):S47-S57. http://dx.doi.org/10.1007/s00280-005-0098-0.
71. Sharifi N, Kawasaki BT, Hurt EM, Farrar WL. 2006. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther 5:901-906. http://dx.doi.org/10.4161/cbt.5.8.2949.
72. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO, Pan D. 2012. Genetic and pharmacological disruption of the TEADYAP complex suppresses the oncogenic activity of YAP. Genes Dev 26:1300-1305. http://dx.doi.org/10.1101/gad.192856.112.
73. Wu S, Liu Y, Zheng Y, Dong J, Pan D. 2008. The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell 14:388-398. http://dx.doi.org/10.1016/j.devcel.2008.01.007.
74. Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W, Zhao J, Chen X, Zhang L, Wang CY, Bastian BC, Zhang K, Guan KL. 2014. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25:822-830. http://dx.doi.org/10.1016/j.ccr.2014.04.017.
75. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. 2012. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 26:54-68. http://dx.doi.org/10.1101/gad.173435.111.
76. Cinar B, Collak FK, Lopez D, Akgul S, Mukhopadhyay NK, Kilicarslan M, Gioeli DG, Freeman MR. 2011. MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling. Cancer Res 71:4303-4313. http://dx.doi.org/10.1158/0008-5472.CAN-10-4532.
77. Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F, Harada S, Schmidt A, Rodan GA, Freedman LP, Bai C. 2004. The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol 18:2011-2023. http://dx.doi.org/10.1210/me.2004-0065.
78. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239-243. http://dx.doi.org/10.1038/nature11125.
79. Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A, Pan D. 2010. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev 24:2383-2388. http://dx.doi.org/10.1101/gad.1978810.
80. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H. 2011. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19:792-804. http://dx.doi.org/10.1016/j.ccr.2011.05.006.
81. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H. 2003. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221. http://dx.doi.org/10.1016/S1535-6108(03)00215-0.
82. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. 2007. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7:64. http://dx.doi.org/10.1186/1471-2407-7-64.